CAMBRIDGE, England,
February 5, 2015 /PRNewswire/ --
Inivata Limited, a clinical cancer genomics company focused on
harnessing the potential of circulating tumour DNA (ctDNA) analysis
to improve cancer testing and treatment, today announces the
appointment of Patrick F. Terry as
Non-Executive Board Director. Patrick has co-founded numerous life
science organizations and has been at the forefront of applied
genomics and personalised medicine for the last 20 years.
In 2000, Patrick and a group of prominent leaders in the fields
of genomics, bioinformatics and biotechnology founded Genomic
Health, Inc. (NASDAQ:GHDX), a pioneering personalized medicine
company based in California. He
has more recently acted as an advisor to multiple life sciences
ventures and founded two other applied genetics companies. Patrick
has served on the boards of companies in North America and Europe and is currently Chief Commercial
Officer at Claritas Genomics.
Patrick has created numerous foundations and philanthropic
organisations including the Personalized Medicine Coalition (PMC)
and the European Personalized Medicine Association (EPEMED). These
organizations were established to advance the understanding of
personalised medicine.
He has published dozens of peer-reviewed scientific papers,
articles, and book chapters in the field of genetics, personalized
medicine, and biomedical research and acts as an editor and advisor
to numerous organisations.
Patrick said of his appointment, "I am very excited by the
clinical applications of Inivata's technology and the potential for
profound influence on therapeutic effectiveness, care delivery,
disease management, and patient outcomes. I believe my experience
in shepherding products through development to clinical delivery
can help guide the Company's development and I look forward to
working with what is already a very strong board and management
team in delivering on the promise of Inivata's world-class
technology."
Inivata CEO Michael Stocum said,
"Patrick is a great person who has seen first-hand the
life-changing benefits that personalised medicine and biotechnology
can offer. His direct experience with genetic disease and
cancer along with his international business expertise make him the
ideal Non-Executive Board Member for Inivata. We are thrilled
to have the advantage he will lend to progressing Inivata's ctDNA
products and business initiatives further."
For more information, please
visit: http://www.inivata.com
About Inivata
Inivata is a clinical cancer genomics company harnessing the
emerging potential of circulating DNA analysis to improve testing
and treatment for oncologists and their patients.
Unlike conventional invasive biopsies, Inivata detects and
analyses genomic material from a cancer patient's cell-free,
circulating tumour DNA (ctDNA) which can be collected through a
simple blood sample. This non-invasive approach - a liquid biopsy -
offers a revolution in how cancer is detected, monitored and
treated.
Inivata is based in Cambridge,
UK and its scientific founders are leading figures in the
ctDNA field: Nitzan Rosenfeld
(Cancer Research UK Cambridge Institute, University of Cambridge), Tim Forshew (UCL Cancer Institute, University
College London), James Brenton
(Cancer Research UK Cambridge Institute, University of Cambridge) and Davina Gale (Cancer Research UK Cambridge
Institute, University of
Cambridge).
Inivata's investors and shareholders include Imperial
Innovations, Johnson & Johnson Innovation - JJDC, Inc.,
Cambridge Innovation Capital and Cancer Research Technology.
Contacts:
Liz Macfadyen
Email: liz.macfadyen@inivata.com
Chris Gardner / Mark Swallow
Citigate Dewe Rogerson
Tel: +44-(0)207-638-9571
Email: chris.gardner@citigatedr.co.uk /
mark.swallow@citigatedr.co.uk
SOURCE Inivata